Dr. Elena Elimova discussed data showing 21-month progression-free survival with Ziihera, Tevimbra and chemotherapy for some patients.
Dr. Elena Elimova
Advertisement
Elimova is a staff medical oncologist at Princess Margaret Cancer Centre in Ontario, Canada, where she is also an associate professor in the Department of Medicine at the University of Toronto.
Articles by Dr. Elena Elimova
Dr. Elena Elimova discusses how Ziihera-based therapy may change treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
FDA Updates Safety Warnings for Common Chemotherapy Drugs
2
FDA Removes Use Limitation for Yescarta in Primary CNS Lymphoma
3
KTX-1001 Elicits Responses in Some With Multiple Myeloma
4
Real-World Data with Amtagvi Show High Response Rates in Advanced Melanoma
5